baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GSK plc/ US37733W2044 /

2024-04-26 10:10:00 PM	Chg. +0.20	Volume	Bid2:00:00 AM	Ask2:00:00 AM	High	Low
41.11USD	+0.49%	2.73 mill. Turnover: 91.82 mill.	40.68Bid Size: 100	41.58Ask Size: 100	41.31	40.87

GlobeNewswire 04-25 Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...

GlobeNewswire 04-23 Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and R...

GlobeNewswire 04-22 Kynos Therapeutics announces positive top-line results from the first-in-human Phase I study of its ...

GlobeNewswire 04-15 Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

GlobeNewswire 04-10 Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atop...

GlobeNewswire 04-09 SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congr...

GlobeNewswire 04-08 Actuate Therapeutics Announces Poster Presentations at the 2024 AACR Annual Meeting

GlobeNewswire 04-08 OMass Therapeutics expands Scientific Advisory Board with the appointment of Sarah Teichmann

GlobeNewswire 04-04 Over 52 Million Myeloma Warriors Reached, Creating Ripples Across the Globe for #MyelomaACTIONMonth

GlobeNewswire 04-03 AAFA's Advocacy for Health Equity Leads to White House Address on Asthma Inhaler Pricing

GlobeNewswire 03-28 SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire 03-27 Algernon Pharmaceuticals Announces Closing of the Acquisition of its Chronic Cough Research Program ...

GlobeNewswire 03-21 LIXTE Provides Update on Progress with LB-100 as a PP2A Inhibitor to Enhance Chemotherapy and Immuno...

GlobeNewswire 03-21 Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GP...

GlobeNewswire 03-18 Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy ...

GlobeNewswire 03-15 American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...

GlobeNewswire 03-13 Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Busi...

GlobeNewswire 03-11 Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire 03-11 4BIO Capital Strengthens Advisory Board and Investment Team

GlobeNewswire 03-06 Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business...

GlobeNewswire 03-06 iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

GlobeNewswire 03-06 Genesis Research Group Announces Appointment of David W. Miller as CEO

GlobeNewswire 03-04 Sitryx Therapeutics makes key appointments to strengthen business operations and progress immunometa...

GlobeNewswire 02-29 Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting

GlobeNewswire 02-28 Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full...

GSK plc/ US37733W2044 /

If you wish to receive reply to your feedback, please provide your email address.